WO2005080977A1 - Method of estimating skin irritation - Google Patents
Method of estimating skin irritation Download PDFInfo
- Publication number
- WO2005080977A1 WO2005080977A1 PCT/JP2005/002902 JP2005002902W WO2005080977A1 WO 2005080977 A1 WO2005080977 A1 WO 2005080977A1 JP 2005002902 W JP2005002902 W JP 2005002902W WO 2005080977 A1 WO2005080977 A1 WO 2005080977A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substance
- skin
- amount
- irritation
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
Definitions
- the present invention relates to a component used for an external preparation such as a preservative, a surfactant, or an organic acid, and a method for predicting the irritation to the skin of the external preparation using skin constituent cells.
- Skin irritation includes so-called stinging stimulation and primary skin irritation.
- Stinging stimulation is a general term for stimuli that cause sensations on the skin, such as “tingling”, “twitching”, “twitching” and “itch”, which are felt when an external preparation such as cosmetics is applied to the skin. Occurs within minutes after application and disappears transiently without inflammatory symptoms.
- Primary skin irritation is an irritation that causes an inflammatory response to the skin, which occurs within hours after application and is usually accompanied by erythema, edema, and inflammatory symptoms.
- the stinging test is a test that is used to evaluate the stinging stimulus.This test is useful for confirming the irritation of external preparations such as cosmetics, especially in the development of cosmetics and external preparations. It is widely used. However, the previous stinging test has shown the subject's subjective feeling.
- Substance P is a neuropeptide consisting of 11 amino acids, is a neurotransmitter of the primary sensory nerve, and is mainly known as a pain information transmitter. Substance P is contained in peripheral nerves and released from nerve endings.Released substance P causes vasodilation and plasma protein leakage, forms erythema and edema, and reduces mast cell decondyles. It promotes the release of histamine and leukotriene, and is a factor that causes primary irritation. Peripheral nerves form a network of sympathetic nerves and unmyelinated sensory nerves (C fibers) mainly in the dermis, and are present particularly around blood vessels, hair follicles and sweat glands.
- C fibers unmyelinated sensory nerves
- peripheral nerves extend from the dermis to the epidermis, and nerve endings are also found in the epidermis such as the basal layer and the spinous layer. It is also known that these nerve ending forces adhere to epidermal keratinocytes, melanocytes and Langernon's cells, which are constituent cells of epidermal cells (see Non-Patent Document 1). In addition, it has been reported that epidermal keratinocytes themselves produce substance P and enhance their own substance P production in a photocrine manner (see Non-Patent Document 2), but almost no physiological significance is known. Not.
- Patent Document 1 JP-A-11-180879
- Patent Document 2 JP-A-2003-240779
- Non-Patent Document 1 Nature 1993 (363), 159-163
- Non-Patent Document 2 Biocnemical and Biophysical Research Communications 1999 (263), 327-333
- An object of the present invention is to provide a simple skin irritation evaluation test method for estimating the irritability of a substance applied to the skin to the skin.
- the present inventors have been studying in order to achieve the above object, and in the process, the amount of neuropeptide released from skin constituent cells, particularly the amount of substance P, has been reduced by the stin of the subject.
- the present inventors have found that the index can be used as an index for predicting the stimulus of the ging, and have completed the present invention.
- the present invention provides a method for evaluating irritation for predicting a skin irritation sensation of a subject, comprising contacting cultured cells with skin constituents with the subject and measuring the amount of substance P. Is provided.
- the skin irritation evaluation method of the present invention (hereinafter also referred to as "evaluation method”) is a simple and highly sensitive method for predicting and evaluating skin irritation using the amount of substance P released from skin constituent cells as an index. It is an entirely new evaluation method that provides an in vitro alternative to the stinging test. Since this test method uses skin culture cells and skin tissues that are inferior to human sensation, objective results can be obtained, reproducibility is high, and it can be performed easily. Furthermore, since skin cultured cells and skin tissues are used, it is possible to easily carry out the test at any time without limiting the number of tests in which the number of subjects required to carry out the test is not required.
- the skin constituent cells are placed in, for example, a culture dish or a culture plate, and an appropriate amount of a nutrient culture solution is added, followed by culturing under commonly used culture conditions.
- the analyte is added to the culture solution.
- collect the culture supernatant at a set time and measure the amount of substance P in the culture supernatant.
- the appropriate stinging positive control treat the skin constituent cells in the same manner as the test subject, and measure substance P in the culture supernatant.
- the amount of substance P is compared between the case where the stinging positive control is used and the case where the subject is used, and the irritation of the subject is evaluated.
- the method of the present invention can also be used as a primary screening method before performing a stinging test by a stinging stimulus evaluation method using humans.
- the number of tests for the stinging stimulus evaluation method using humans as subjects is limited due to problems such as the number of subjects. Therefore, the method of the present invention can be used as a primary screening method for excluding a clearly stimulus-positive subject from an experimental subject in vivo in advance. This will enable efficient development of hypoallergenic products with more secure safety.
- the subject that can be evaluated by the present invention is not particularly limited as long as it is a substance or composition widely applied to the skin, but various preservatives, fragrances, surfactants, dyes, solubilizers, gels Agents, thickeners, emulsifiers, fats and oils, amino acids, saccharides, water-soluble polymers, organic acids, base components and compositions containing these.
- the surfactant include a cationic surfactant, an anionic surfactant, a nonionic surfactant, and an amphoteric surfactant.
- the composition include various external preparations, for example, cosmetics, medicinal external preparations, various cleaning agents (detergent, stone, hair cleaning agent, liquid cleaning agent) and the like.
- the skin constituent cells used in the present invention include epidermal keratinocytes (epidermal keratinocytes), skin fibroblasts, Langernon's cells, melanocytes, hair matrix cells, and hair, which are skin cells. Papillary cells and the like.
- skin keratinocytes which are easily susceptible to external stimuli and are preferred by skin epidermal constituent cells (eg, epidermal keratinocytes, Langerhans cells, melanocytes, etc.) which are cells constituting the epidermal part of the skin are particularly preferable.
- skin epidermal constituent cells eg, epidermal keratinocytes, Langerhans cells, melanocytes, etc.
- One type of skin constituent cells may be used, or a plurality of cells may be used as a mixture.
- the skin constituent cells may be monolayer cultured cells or multilayer cultured cells, or may be three-dimensional cultured skin composed of a plurality of skin constituent cells. Human skin-derived cells are preferred since they can be used for the purpose of the power stinging test.
- Cultured cells can be used as skin constituent cells, or they may be prepared from skin tissue by a conventional method.
- cultured cells can be established by a method known to those skilled in the art, or can be obtained from commercial products.
- Some epidermal keratinocytes are commercially available as cultured cells, and they can be easily obtained.
- primary and secondary culture cells of human epidermal keratinocytes, HaCaT keratinocyte strain, and the like can be used.
- As commercially available cultured cells of epidermal keratinocytes for example, Epidercell NHEK (F), Epidercell NHEK (B) (both manufactured by Kurabo Industries) can be used.
- TESTSKIN TM Toyobo
- TESTSKIN TM is an example of a three-dimensional cultured skin (model).
- the skin constituent cells used in the test are cultured under a normal culture condition using an appropriate medium, and those that have survived before contact with the subject can be used, and those that have become subconfluent It is preferable to use As the medium, supplementary reagents (insulin, epidermal growth factor, hydration, etc.) suitable for commonly used basic media (iso-osmotic pH equilibration solution mixed with salts, amino acids, sugars, vitamins and other trace essential nutrients) are used. Mouth cortisone, pituitary pituitary extract, etc.) or serum.
- KG_2 manufactured by Kurabo Industries
- K-110 manufactured by Kyokuto Pharmaceutical
- EpiLife TM manufactured by Cascade
- KG_2 manufactured by Kurabo Industries
- K-110 manufactured by Kyokuto Pharmaceutical
- EpiLife TM manufactured by Cascade
- Skin fibroblasts are used, Fibro cells (Kurabo) can be used as cultured cells, and Medium 106S (Kurabo) can be used as a culture medium.
- Medium 106S (Kurabo) can be used as a culture medium.
- the cell or skin model is used in principle. The instructions in the instruction manual for the model may be followed.
- the treatment of the skin constituent cells by the subject is preferably carried out, for example, by culturing the skin constituent cells and adding the subject to a culture solution.
- a culture solution a medium, an isotonic buffer, a physiological saline, or the like can be used as long as the cells can survive the cells.
- the stinging stimulus is a stimulus that occurs within a few minutes after application
- the treatment time of the subject and skin constituent cells is 0.5 to 60 minutes, preferably 1 to 30 minutes, more preferably 1 to 10 minutes, and most preferably. One five minutes is fine.
- the present invention can be implemented by performing processing longer or shorter than the above.
- the treatment conditions are not particularly limited as long as the cells do not die and the substance P is released into the culture solution, but the culture during the treatment is usually performed at a temperature in the range of room temperature to about 40 ° C, preferably About 35 40 ° C, 3-7% CO condition, especially 37 ° C
- the concentration of the analyte to be added varies depending on the purpose of use and the type of the analyte. Usually, the final concentration is preferably 0.000001 to 10% by weight, particularly preferably 0.001 to 1% by weight. . In general, if the concentration of such a compound is also high, it exhibits some effect including toxicity on cells, so that a concentration of 10% by weight or more is not preferable. A low concentration of less than 0.000001% by weight is not preferable because it is unlikely to be used and is difficult to formulate.
- the amount of substance P can be measured more easily with better reproducibility by measuring a force protein that can be expressed by the amount of substance P mRNA or the amount of protein.
- a force protein that can be expressed by the amount of substance P mRNA or the amount of protein.
- the amount (protein content) of substance P itself is measured. Yes.
- the culture is usually performed within 0.5 minutes to 1 hour, preferably within 110 minutes, even more preferably within 110 minutes, and most preferably within 15 minutes. What is necessary is just to start measuring the amount of substance P during the cleaning.
- the measurement method is not particularly limited, and a commonly used general measurement method is used.
- the amount of substance P may be measured directly by measuring the amount in the supernatant of the culture solution, but can also be measured indirectly by using an antibody such as ELISA or immunochromatography.
- a method for directly measuring substance P include, but are not limited to, high performance liquid chromatography.
- the method of indirect measurement is not limited to the ability to use a commonly used competitive method or sandwich attestation method, which is preferably an immunological measurement method using an anti-substance P antibody.
- a labeled antibody a direct label (a label such as colloidal gold or a fluorescent substance) or an enzyme-labeled antibody can be used.
- Antibodies used for the measurement can be prepared by using commercially available antibodies or by methods known to those skilled in the art.
- the anti-substance P antibody a monoclonal antibody or a polyclonal antibody can be used, and a commercially available product can be obtained from Santa Cruz or Zymmet.
- a commercially available substance P amount measurement kit can be used.Substance P ELISA (R & D Systems Inc.), Substance P, EIA Kit (Cayman Chemical Company), Substance P, EIA High Sensitivity Kit ( Peninsula Laboratories, Inc.).
- the method of measuring the amount of substance P by ELISA using the competitive method add the culture supernatant and the substance P standard solution to a 96-well plate coated with an appropriate amount of anti-magpie polyclonal antibody (goat).
- a test system using a compound known to cause stinging as a positive control and a test system using a test subject are used in a medium.
- a method of comparing the amount of substance P may be mentioned.
- the amount of substance P in the medium of the test system using the subject is equal to or greater than the amount of substance P in the medium of the test system using the positive control, the subject is stinging to the skin. Is determined.
- the amount of substance P in the culture medium of the test system using the subject may be 90% or more, 80% or more, and 70% or more of the amount of substance P in the culture medium of the test system using the positive control.
- a positive control can be appropriately selected depending on the purpose of a force test in which phenoxyethanol, methylparaben, lactic acid, and the like can be used, the cultured cells to be used, and the like.
- a subject in another embodiment, can be evaluated without using a positive control as described above.
- cultured skin constituent cells and the like are treated in the same manner as described above, the culture supernatant is collected, and the amount of substance P in the supernatant is measured.
- the cells and skin model, culture conditions, and the method for measuring and evaluating substance P that can be used in this embodiment are substantially the same as described above.
- the case of the evaluation methods using normal human epidermal keratinocytes are preferably, substance P amount detected on the upper brass five minutes after the culture supernatant harvested force of about 2.5 pg / l X 10 5 cells or more
- the stinging stimulus is false positive, and when it is about lOpg / 1 ⁇ 10 5 cells or more, it can be determined that the stinging stimulus is positive.
- the evaluation method of this embodiment is particularly useful as a primary screening before a stinging test in humans.
- the power-off value can be set appropriately as desired.
- the screen of the positive substance or the positive preparation of the stinging stimulus using the release amount of substance P in the skin constituent cells by the subject as an index is obtained.
- a method is provided.
- the evaluation method of the present invention does not rely on a conventional sensory judgment method, can provide an objective and quantitative evaluation for each subject, and is useful as a simple screening method.
- the present invention also provides a measurement kit for predicting skin irritation of a subject.
- This kit contains, for example, cultured skin constituent cells that release substance P upon contact with a stinging stimulus-positive substance, and reagents for measuring the amount of substance P.
- reagents for measuring the amount of substance P include anti-substance P antibody, labeled anti-substance P antibody, labeled substance P (solution), and a known amount of substance P to be used as a control standard. Power that is not limited to these.
- a stinging stimulus-positive substance such as phenoxyethanol, methylparaben, or lactic acid, preferably methylparaben may be contained.
- the kit composition includes an incubator inoculated with epidermal keratinocytes, a culture solution for epidermal keratinocytes, and a reagent for measuring the amount of substance P.
- the substance P amount measurement reagent is, for example, a substance P amount measurement ELISA reagent.
- this kit may contain methyl paraben as a positive control.
- This kit stimulates cells by adding a culture solution in which a test sample is dispersed or dissolved to a plate prepared by seeding an appropriate amount of epidermal keratinocytes on a 96-well plate, and stimulating cells after a certain period of time. It can be used by measuring the amount of P using an ELISA reagent for measuring the amount of substance P.
- a measurement kit for another embodiment of the present invention (evaluation method without using a comparison control) can also be constituted according to the above, and a method for constructing such a kit is known to those skilled in the art.
- the substance P amount was measured by the ELISA method.
- Normal human epidermal keratinocytes (Epidercell NHEK (B)) were seeded on a 24-well plate at 2 x 10 5 cells / well, and 37 ° C using 1 ml of epidermal keratinocyte culture medium KG-2 (Kurabo). And cultured under 5% CO. When the medium becomes subconfluent, replace the medium and adjust to the specified final concentration in the well. Each of the test samples was added in an amount of 10/1. The culture supernatant was collected 5 minutes and 10 minutes thereafter. Substance P in the collected culture supernatant was quantified by substance P ELISA (manufactured by R & D Systems Inc.).
- This evaluation method uses the amount of substance released from the skin constituent cells in the culture solution as an index. It is a method for predicting the skin irritation of a subject, and it is particularly useful for the development of external preparations because components and compositions that may cause skin troubles can be easily selected in vitro. Furthermore, according to the present invention, skin irritation of an external preparation such as a preservative, a surfactant or an organic acid and a cosmetic containing them can be evaluated in vitro with high sensitivity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
明 細 書 Specification
皮膚刺激性評価方法 Skin irritation evaluation method
技術分野 Technical field
[0001] 本発明は、防腐剤、界面活性剤または有機酸などの外用剤に用レ、られる成分並び に外用剤の皮膚に対する刺激性を皮膚構成細胞を用いて予測する方法に関する。 背景技術 The present invention relates to a component used for an external preparation such as a preservative, a surfactant, or an organic acid, and a method for predicting the irritation to the skin of the external preparation using skin constituent cells. Background art
[0002] 近年、敏感肌を訴える人が増加しており、敏感肌用の低刺激性化粧品や医薬品、 医薬部外品が多数上市されている。現代生活における敏感肌の原因として、生活様 式の変化 (冷暖房による生活環境の乾燥化、食生活の変化など)、紫外線などの環境 因子、また内面的な要因であるストレス等が考えられている。し力 ながら敏感肌とい つても、医療現場や化粧品業界で明確な定義付けがされているわけではなぐ低刺 激性化粧品や医薬品、医薬部外品については各供給者が独自に判断し、宣伝、販 売しているのが実情である。 [0002] In recent years, the number of people complaining of sensitive skin has increased, and a large number of hypoallergenic cosmetics, pharmaceuticals, and quasi-drugs for sensitive skin have been put on the market. Possible causes of sensitive skin in modern life include changes in lifestyle (drying of living environment due to cooling and heating, changes in eating habits, etc.), environmental factors such as ultraviolet rays, and stress that is an internal factor. . However, the definition of sensitive skin is not clearly defined in the medical practice or cosmetics industry, and each supplier independently determines and promotes low irritating cosmetics, pharmaceuticals, and quasi-drugs. The fact is that they are sold.
[0003] 従って、低刺激性商品として市販されているものであっても、刺激性が同程度であ るとも言えず、消費者が望む刺激レベルの商品を選択できないのが現状である。 [0003] Therefore, even if they are marketed as low-irritation products, they cannot be said to be of the same level of irritation, and at present it is not possible to select products with a stimulation level desired by consumers.
[0004] 皮膚刺激には、スティンギング刺激と皮膚一次刺激と呼ばれるものがある。スティン ギング刺激は、化粧料等の外用剤を皮膚に塗布した際に感じる「ヒリヒリ」、「ピリピリ」 、「つっぱり感」や「かゆみ」といった感覚を皮膚に引き起こす刺激の総称で、この感 覚は塗布後数分以内に生じ、炎症性の症状を伴わず、一過性に消失する。一方、皮 膚一次刺激は、皮膚に炎症反応を引き起こす刺激で、この反応は塗布後数時間以 内に生じ、通常紅斑や浮腫とレ、つた炎症性の症状を伴う。 [0004] Skin irritation includes so-called stinging stimulation and primary skin irritation. Stinging stimulation is a general term for stimuli that cause sensations on the skin, such as "tingling", "twitching", "twitching" and "itch", which are felt when an external preparation such as cosmetics is applied to the skin. Occurs within minutes after application and disappears transiently without inflammatory symptoms. Primary skin irritation, on the other hand, is an irritation that causes an inflammatory response to the skin, which occurs within hours after application and is usually accompanied by erythema, edema, and inflammatory symptoms.
[0005] 皮膚一次刺激は、モルモット、ゥサギ、ヒトなどを対象とした皮膚パッチ試験等で確 認できる。これに対して、スティンギング刺激は感覚刺激であるため、実験動物による 評価は困難であり、刺激感評価はもっぱらヒトの感覚に基いて行われている。スティン ギング刺激を評価するために行う試験をスティンギング試験とレ、い、特に化粧料等の 外用剤の刺激性を確認するために有用な試験であり、化粧料や外用剤の開発にお いて汎用されている。しかし、これまでのスティンギング試験は被験者の主観的な感 覚をスコアにするため、個人の感受性の違いや、季節による影響、さらに人種差等、 種々の理由により客観性を欠き、十分に満足できるものではなかった。さらに、被験 者の特定の部位に試験物質を塗布して測定する試験であるため、被験者数により 1 回の試験人数が制限されてしまうという欠点があった。従って、低刺激性についての 統一的な判断基準となり得る客観的な評価を提供する、簡便なスティンギング試験に 対する必要性が存在してレ、た。 [0005] Primary skin irritation can be confirmed by a skin patch test or the like for guinea pigs, porpies, humans and the like. On the other hand, since the stinging stimulus is a sensory stimulus, evaluation by an experimental animal is difficult, and the stimulus sensation evaluation is performed based solely on human sensation. The stinging test is a test that is used to evaluate the stinging stimulus.This test is useful for confirming the irritation of external preparations such as cosmetics, especially in the development of cosmetics and external preparations. It is widely used. However, the previous stinging test has shown the subject's subjective feeling. In order to score the sense of sensation, there was a lack of objectivity for various reasons, such as differences in individual sensitivity, effects of seasons, and racial differences, and was not fully satisfactory. Furthermore, since the test is performed by applying the test substance to a specific part of the subject, the number of test subjects is limited by the number of subjects. Therefore, there was a need for a simple stinging test that provided an objective assessment that could be a unified criteria for hypoallergenicity.
[0006] サブスタンス P(SP)は 11個のアミノ酸からなる神経ペプチドで、一次知覚神経の神経 伝達物質であり、主として痛覚情報伝達物質として知られている。サブスタンス Pは末 梢神経に含有されており、神経終末から遊離され、放出されたサブスタンス Pは血管 拡張や血漿蛋白の漏出をもたらしたり、紅斑や浮腫を形成したり、肥満細胞の脱顆 粒を促進して、ヒスタミンやロイコトリェンなどを遊離させ、一次刺激を引き起こす要因 ともなる。末梢神経は、主として真皮内において交感神経、および無髄知覚神経(C 繊維)がネットワークを形成し、特に血管、毛嚢および汗腺周囲に存在している。この 末梢神経の一部は、真皮から表皮に伸び、神経終末は基底層、有棘層などの表皮 の各層にも見出されている。そして、これらの神経終末力 表皮細胞の構成細胞であ る表皮ケラチノサイト、メラノサイトおよびランゲルノヽンス細胞と接着することも知られて いる(非特許文献 1参照)。また、表皮ケラチノサイトが自らサブスタンス Pを産生し、ォ 一トクライン的に自身のサブスタンス P産生を亢進させることが報告されている(非特 許文献 2参照)が、その生理的な意義についてはほとんど知られていない。 [0006] Substance P (SP) is a neuropeptide consisting of 11 amino acids, is a neurotransmitter of the primary sensory nerve, and is mainly known as a pain information transmitter. Substance P is contained in peripheral nerves and released from nerve endings.Released substance P causes vasodilation and plasma protein leakage, forms erythema and edema, and reduces mast cell decondyles. It promotes the release of histamine and leukotriene, and is a factor that causes primary irritation. Peripheral nerves form a network of sympathetic nerves and unmyelinated sensory nerves (C fibers) mainly in the dermis, and are present particularly around blood vessels, hair follicles and sweat glands. Some of these peripheral nerves extend from the dermis to the epidermis, and nerve endings are also found in the epidermis such as the basal layer and the spinous layer. It is also known that these nerve ending forces adhere to epidermal keratinocytes, melanocytes and Langernon's cells, which are constituent cells of epidermal cells (see Non-Patent Document 1). In addition, it has been reported that epidermal keratinocytes themselves produce substance P and enhance their own substance P production in a photocrine manner (see Non-Patent Document 2), but almost no physiological significance is known. Not.
[0007] ところで、敏感肌の状態に共通する生理病理学的パターンが、皮膚におけるタキキ ニン、特にサブスタンス Pの放出能力の高さに関連していることが報告されている。さ らに、サブスタンス pアンタゴニストの使用により、敏感肌に対する予防および Zまた は治療効果を得ることが出来ることや、表皮および真皮の神経終末から生じるタキキ ニンの放出原因となるカブサイシンを患者の皮膚に塗布する事により皮膚が敏感で あるか否力、を決定するための試験方法が知られている(特許文献 1参照)。 [0007] By the way, it has been reported that a physiopathological pattern common to the state of sensitive skin is related to the high ability of skin to release tachykinin, particularly substance P. In addition, the use of substance p antagonists can provide prophylactic and / or Z- or therapeutic effects on sensitive skin, and cabsaicin, which causes the release of tachykinin from epidermal and dermal nerve endings, can be applied to patient skin. A test method for determining whether or not the skin is sensitive by application is known (see Patent Document 1).
[0008] また、一次刺激の評価方法であるパッチテストに代わる 3次元的組織培養物を用い た被検体の刺激性試験評価方法が知られてレ、る(特許文献 2参照)。 [0008] In addition, a method for evaluating a test for irritation of a subject using a three-dimensional tissue culture instead of a patch test, which is a method for evaluating a primary stimulus, is known (see Patent Document 2).
[0009] しかしながら、スティンギング試験 (刺激感評価試験)の代替方法となる培養細胞を 用いた試験方法は未だ知られてレヽなレ、。 [0009] However, cultured cells that can be used as an alternative to the stinging test (stimulation evaluation test) are not available. The test method used is still known.
[0010] 特許文献 1 :特開平 11-180879号公報 Patent Document 1: JP-A-11-180879
特許文献 2:特開 2003-240779号公報 Patent Document 2: JP-A-2003-240779
非特許文献 1 : Nature 1993(363), 159-163 Non-Patent Document 1: Nature 1993 (363), 159-163
非特許文献 2: Biocnemical and Biophysical Research Communications 1999(263), 327-333 Non-Patent Document 2: Biocnemical and Biophysical Research Communications 1999 (263), 327-333
発明の開示 Disclosure of the invention
発明が解決しょうとする課題 Problems to be solved by the invention
[0011] 本発明の目的は、皮膚に適用する物質の皮膚に対する刺激感を予測するための、 簡便な皮膚刺激性評価試験方法を提供することにある。 [0011] An object of the present invention is to provide a simple skin irritation evaluation test method for estimating the irritability of a substance applied to the skin to the skin.
課題を解決するための手段 Means for solving the problem
[0012] 力、かる実情に鑑み、本発明者らは上記目的を達成するために検討を重ね、その過 程で皮膚構成細胞から放出される神経ペプチド量、特にサブスタンス P量が被検体 のスティンギング刺激性を予測するための指標となりうることを見出し、本発明を完成 するに至った。 [0012] In view of the power and the actual situation, the present inventors have been studying in order to achieve the above object, and in the process, the amount of neuropeptide released from skin constituent cells, particularly the amount of substance P, has been reduced by the stin of the subject. The present inventors have found that the index can be used as an index for predicting the stimulus of the ging, and have completed the present invention.
[0013] 従って、本発明は、皮膚構成培養細胞と被検体を接触させ、サブスタンス P量を測 定することを特徴とする、当該被検体の皮膚刺激感を予測するための、刺激性評価 方法を提供するものである。 [0013] Accordingly, the present invention provides a method for evaluating irritation for predicting a skin irritation sensation of a subject, comprising contacting cultured cells with skin constituents with the subject and measuring the amount of substance P. Is provided.
発明の効果 The invention's effect
[0014] 本発明の皮膚刺激性評価法 (以下、「評価法」ともいう)は皮膚構成細胞から放出さ れたサブスタンス P量を指標に、簡便でかつ高感度に皮膚に対する刺激感を予測評 価する全く新しい評価方法であり、スティンギング試験の in vitroでの代替試験方法を 提供するものである。この試験方法ではヒトの感覚ではなぐ皮膚培養細胞や皮膚組 織を使用するため、客観的な結果を得ることができ再現性が高ぐしかも容易に実施 する事ができる。さらに、皮膚培養細胞や皮膚組織を使用するので、被験者を試験 実施に必要な数だけ確保する必要がなぐ試験回数が制限されることなく簡便にい つでも試験することができる。 [0015] 本発明の一つの態様では、まず、皮膚構成細胞を、例えば培養シャーレや培養プ レートに入れ、さらに、栄養培養液を適量加え、通常用いる培養条件で培養する。次 いで、培養液に被検体を添加する。添加後、設定された時間に培養上清を採取し、 その培養上清中のサブスタンス Pの量を測定する。適当なスティンギング陽性対照を 用いて被験体と同様に皮膚構成細胞を処理し、培養上清中のサブスタンス Pを測定 する。次いで、サブスタンス Pの量を、スティンギング陽性対照を用いた場合と被検体 を用いた場合で比較し、被検体の刺激性を評価する。本評価方法を行うことで、ステ インギング刺激に関連する被検体のスクリーニングを的確かつ簡便に行うことが可能 であり、スティンギング刺激陽性物質や製剤(特に外用剤)のスクリーニング方法とし て使用可能である。 [0014] The skin irritation evaluation method of the present invention (hereinafter also referred to as "evaluation method") is a simple and highly sensitive method for predicting and evaluating skin irritation using the amount of substance P released from skin constituent cells as an index. It is an entirely new evaluation method that provides an in vitro alternative to the stinging test. Since this test method uses skin culture cells and skin tissues that are inferior to human sensation, objective results can be obtained, reproducibility is high, and it can be performed easily. Furthermore, since skin cultured cells and skin tissues are used, it is possible to easily carry out the test at any time without limiting the number of tests in which the number of subjects required to carry out the test is not required. [0015] In one embodiment of the present invention, first, the skin constituent cells are placed in, for example, a culture dish or a culture plate, and an appropriate amount of a nutrient culture solution is added, followed by culturing under commonly used culture conditions. Next, the analyte is added to the culture solution. After the addition, collect the culture supernatant at a set time, and measure the amount of substance P in the culture supernatant. Using the appropriate stinging positive control, treat the skin constituent cells in the same manner as the test subject, and measure substance P in the culture supernatant. Next, the amount of substance P is compared between the case where the stinging positive control is used and the case where the subject is used, and the irritation of the subject is evaluated. By using this evaluation method, it is possible to accurately and easily screen for subjects related to stinging stimuli, and it can be used as a screening method for stinging stimulus-positive substances and preparations (particularly external preparations). is there.
[0016] また、本発明の方法は、ヒトを用いたスティンギング刺激性評価方法によるスティン ギング試験を行う前の一次スクリーニング方法として用いることもできる。前述したよう に、ヒトを被験者として用いるスティンギング刺激性評価方法は被験者数等の問題に よりその試験回数が限られる。それゆえ、予め明らかに刺激陽性の被検体をインビボ での実験被検体から除外するための一次スクリーニング方法として、本発明の方法を 用いることができる。これにより、安全性をより確実にした低刺激性製品の効率よい開 発が可能となる。 The method of the present invention can also be used as a primary screening method before performing a stinging test by a stinging stimulus evaluation method using humans. As described above, the number of tests for the stinging stimulus evaluation method using humans as subjects is limited due to problems such as the number of subjects. Therefore, the method of the present invention can be used as a primary screening method for excluding a clearly stimulus-positive subject from an experimental subject in vivo in advance. This will enable efficient development of hypoallergenic products with more secure safety.
[0017] 本発明により評価できる被検体としては、広く皮膚に対して適用する物質や組成物 であれば特に制限されないが、種々の防腐剤、香料、界面活性剤、色素、可溶化剤 、ゲル化剤、増粘剤、乳化剤、油脂類、アミノ酸類、糖類、水溶性高分子、有機酸、 基剤成分およびこれらを含有する組成物が挙げられる。ここで、界面活性剤としては 、陽イオン性界面活性剤、陰イオン性界面活性剤、非イオン性界面活性剤、両性界 面活性剤のいずれも挙げられる。また、当該組成物としては、種々の外用剤、例えば 、化粧料、薬用外用剤、各種洗浄剤 (洗剤、石鹼、頭髪用洗浄剤、液体洗浄剤)等が 挙げられる。これらの被検体は精製水またはエタノールなどの適当な溶媒に溶解して 用いることができる。添加する溶媒の量は細胞に対して毒性を示さない量であればよ ぐ溶媒の種類によっても異なる力 培養液の 20%以下、好ましくは 10%以下の添カロ 量が好ましい。 [0018] 本発明で用いる皮膚構成細胞としては、皮膚を構成する細胞であればよぐ表皮ケ ラチノサイト (表皮角化細胞)、皮膚線維芽細胞、ランゲルノヽンス細胞、メラノサイト、 毛母細胞、毛乳頭細胞等が挙げられる。特に、外界からの刺激を受けやすい、皮膚 の表皮部分を構成する細胞である皮膚表皮構成細胞(例えば、表皮ケラチノサイト、 ランゲルハンス細胞、メラノサイト等)が好ましぐ表皮ケラチノサイトが特に好ましい。 皮膚構成細胞は、 1種類でも良いし、複数を混ぜて使用してもよい。評価に用いる場 合、皮膚構成細胞は、単層培養細胞でも多層培養細胞でもよぐまた、複数の皮膚 構成細胞からなる 3次元培養皮膚でもよい。皮膚構成細胞は、ヒトゃゥサギ等の動物 より採取されたものを用いることができる力 スティンギング試験の評価対象がヒトであ ることから、ヒト由来の細胞が好ましい。皮膚構成細胞としては、培養された細胞を用 レ、ることができ、また、皮膚組織から常法により調製してもよい。さらに、培養細胞とし て樹立してレ、る細胞を用いる事が好ましレ、。そのような培養細胞は当業者に既知の 方法で樹立することができ、あるいは、市販品から入手可能である。表皮ケラチノサイ トは培養細胞として市販されているものもあり、それらを容易に入手し得る。例えば、ヒ ト表皮ケラチノサイトの初代培養細胞や二次培養細胞、 HaCaT keratinocyte株等が 使用できる。市販の表皮ケラチノサイト培養細胞としては、例えば、 Epidercell NHEK(F)、 Epidercell NHEK(B) (ともに、クラボウ社製)などを用いることができる。また 、 3次元培養皮膚(モデル)の例として、 TESTSKIN™ (東洋紡)が挙げられる。 [0017] The subject that can be evaluated by the present invention is not particularly limited as long as it is a substance or composition widely applied to the skin, but various preservatives, fragrances, surfactants, dyes, solubilizers, gels Agents, thickeners, emulsifiers, fats and oils, amino acids, saccharides, water-soluble polymers, organic acids, base components and compositions containing these. Here, examples of the surfactant include a cationic surfactant, an anionic surfactant, a nonionic surfactant, and an amphoteric surfactant. Examples of the composition include various external preparations, for example, cosmetics, medicinal external preparations, various cleaning agents (detergent, stone, hair cleaning agent, liquid cleaning agent) and the like. These analytes can be used after being dissolved in an appropriate solvent such as purified water or ethanol. The amount of the solvent to be added may vary depending on the type of the solvent, as long as it does not show toxicity to the cells. The added amount of the calorie is preferably 20% or less, more preferably 10% or less of the culture medium. [0018] The skin constituent cells used in the present invention include epidermal keratinocytes (epidermal keratinocytes), skin fibroblasts, Langernon's cells, melanocytes, hair matrix cells, and hair, which are skin cells. Papillary cells and the like. In particular, skin keratinocytes which are easily susceptible to external stimuli and are preferred by skin epidermal constituent cells (eg, epidermal keratinocytes, Langerhans cells, melanocytes, etc.) which are cells constituting the epidermal part of the skin are particularly preferable. One type of skin constituent cells may be used, or a plurality of cells may be used as a mixture. When used for evaluation, the skin constituent cells may be monolayer cultured cells or multilayer cultured cells, or may be three-dimensional cultured skin composed of a plurality of skin constituent cells. Human skin-derived cells are preferred since they can be used for the purpose of the power stinging test. Cultured cells can be used as skin constituent cells, or they may be prepared from skin tissue by a conventional method. Furthermore, it is preferable to use established cells as cultured cells. Such cultured cells can be established by a method known to those skilled in the art, or can be obtained from commercial products. Some epidermal keratinocytes are commercially available as cultured cells, and they can be easily obtained. For example, primary and secondary culture cells of human epidermal keratinocytes, HaCaT keratinocyte strain, and the like can be used. As commercially available cultured cells of epidermal keratinocytes, for example, Epidercell NHEK (F), Epidercell NHEK (B) (both manufactured by Kurabo Industries) can be used. TESTSKIN ™ (Toyobo) is an example of a three-dimensional cultured skin (model).
[0019] 試験に使用する皮膚構成細胞は通常の培養条件で適当な培地を用いて培養し、 被検体の接触前までは生存しているものを用いることができ、サブコンフルェントとな つたものを用いることが好ましい。培地としては、一般的に使用されている基本培地( 塩類、アミノ酸、糖、ビタミンおよびその他の微量必須栄養素を混合した等浸透圧性 pH平衡溶液)に適当な補助試薬 (インスリン、上皮成長因子、ハイド口コーチゾン、ゥ シ脳下垂体抽出液など)または血清を加えたものを使用できる。市販の表皮ケラチノ サイト培養液としては、 KG_2(クラボウ社製)、 K-110(極東製薬製)、 EpiLife™(Cascade 社製)等が使用できる。また、皮膚線維芽細胞を用レ、る場合には、培養細胞として Fibro cell (クラボウ社製)を、培地として Medium 106S (クラボウ社製)を用いることができ る。なお、市販の細胞や皮膚モデルを使用する場合には、原則として該細胞や皮膚 モデルの使用説明書の指示に従えばよい。 [0019] The skin constituent cells used in the test are cultured under a normal culture condition using an appropriate medium, and those that have survived before contact with the subject can be used, and those that have become subconfluent It is preferable to use As the medium, supplementary reagents (insulin, epidermal growth factor, hydration, etc.) suitable for commonly used basic media (iso-osmotic pH equilibration solution mixed with salts, amino acids, sugars, vitamins and other trace essential nutrients) are used. Mouth cortisone, pituitary pituitary extract, etc.) or serum. As a commercially available culture solution of epidermal keratinocytes, KG_2 (manufactured by Kurabo Industries), K-110 (manufactured by Kyokuto Pharmaceutical), EpiLife ™ (manufactured by Cascade) and the like can be used. When skin fibroblasts are used, Fibro cells (Kurabo) can be used as cultured cells, and Medium 106S (Kurabo) can be used as a culture medium. When a commercially available cell or skin model is used, the cell or skin model is used in principle. The instructions in the instruction manual for the model may be followed.
[0020] 被検体による皮膚構成細胞の処理は、例えば皮膚構成細胞を培養してレ、る培養液 中に当該被検体を添加して培養することにより行うのが好ましい。培養液としては、細 胞が生存できる液であればよぐ培地、等張化された緩衝液、生理食塩水などを用い ること力 sできる。スティンギング刺激は塗布後数分以内に生じる刺激であるため、被検 体と皮膚構成細胞の処理時間は 0.5— 60分、好ましくは 1一 30分、さらに好ましくは 1 一 10分、最も好ましくは 1一 5分あればよい。ただし、場合により、上記よりも長時間ま たは短時間処理することによつても本発明を実施することは可能である。 [0020] The treatment of the skin constituent cells by the subject is preferably carried out, for example, by culturing the skin constituent cells and adding the subject to a culture solution. As a culture solution, a medium, an isotonic buffer, a physiological saline, or the like can be used as long as the cells can survive the cells. Since the stinging stimulus is a stimulus that occurs within a few minutes after application, the treatment time of the subject and skin constituent cells is 0.5 to 60 minutes, preferably 1 to 30 minutes, more preferably 1 to 10 minutes, and most preferably. One five minutes is fine. However, in some cases, the present invention can be implemented by performing processing longer or shorter than the above.
処理条件は細胞が死滅せず、培養液中にサブスタンス Pが放出される条件であれ ば、特に限定されないが、処理時の培養は、通常、室温から約 40°Cの範囲の温度、 好ましくは約 35 40°C、 3-7% CO条件下、特に、 37°C The treatment conditions are not particularly limited as long as the cells do not die and the substance P is released into the culture solution, but the culture during the treatment is usually performed at a temperature in the range of room temperature to about 40 ° C, preferably About 35 40 ° C, 3-7% CO condition, especially 37 ° C
2 、 5%CO条件下が好まし 2,5% CO condition is preferred
2 2
レ、。処理後、直ちに培養上清を採取し、サブスタンス P量を測定する。 Les ,. Immediately after the treatment, collect the culture supernatant and measure the amount of substance P.
[0021] 添加される被検体の濃度は、使用目的や被検体の種類により異なるが、通常、最 終濃度として 0.000001— 10重量%であることが好ましぐ特に 0.001— 1重量%が好ま しい。一般的にレ、かなる化合物も高濃度であれば、細胞に対して毒性を含む何らか の作用を示すため、 10重量%以上の濃度は好ましくない。また 0.000001重量%未満 の低濃度の場合は、使用される可能性が低ぐまた、製剤化も難しいため好ましくな レ、。 [0021] The concentration of the analyte to be added varies depending on the purpose of use and the type of the analyte. Usually, the final concentration is preferably 0.000001 to 10% by weight, particularly preferably 0.001 to 1% by weight. . In general, if the concentration of such a compound is also high, it exhibits some effect including toxicity on cells, so that a concentration of 10% by weight or more is not preferable. A low concentration of less than 0.000001% by weight is not preferable because it is unlikely to be used and is difficult to formulate.
[0022] 本発明においては、現在、化粧品や各種洗浄剤に用いられている化合物について 、各種濃度で培養液中のサブスタンス P量について検討した結果、特に化合物の濃 度が 0.01— 1重量%の範囲におけるサブスタンス P量と、スティンギング刺激試験に おける刺激感評価とがよく相関することが明らかになった。従って、被検体として用い る化合物は、 0.01 1重量%の濃度範囲で試験することが特に好ましい。しかし、こ の濃度範囲は被検体として用いる化合物、試験に用いる皮膚構成細胞、 目的製品 の種類などに依存して変動し、限定的なものでない。 [0022] In the present invention, as for the compounds currently used in cosmetics and various cleaning agents, as a result of examining the amount of substance P in the culture solution at various concentrations, particularly when the concentration of the compound is 0.01-1% by weight. It was found that the substance P content in the range correlated well with the stimulus evaluation in the stinging stimulus test. Therefore, it is particularly preferable to test compounds used as analytes in a concentration range of 0.011% by weight. However, this concentration range varies depending on the compound used as the analyte, the skin constituent cells used in the test, the type of the target product, and the like, and is not limited.
[0023] サブスタンス P量はサブスタンス Pの mRNA量や蛋白質量で表すことができる力 蛋 白質を測定する方が再現性もよぐ容易に測定できる。以降、サブスタンス P量と表し た場合には、特に限定しない限り、サブスタンス Pそのものの量 (蛋白質量)を測定して いる。サブスタンス P量を測定する場合、培養細胞等の処理が終了した後、直ちに培 養上清を採取し、速やかに測定を開始することが好ましい。上清の採取から 1時間以 内、好ましくは数十分以内、より好ましくは 30分以内、さらに好ましくは 10分以内、な お好ましくは 5分以内、特に好ましくは数分一数秒以内に測定を開始する。操作に要 する時間を考慮すると、通常、 0.5分一 1時間以内、好ましくは、 1一 30分以内、さらに より好ましくは、 1一 10分以内、最も好ましくは、 1一 5分以内に培養上清中のサブスタ ンス P量の測定を開始すればよい。測定方法としては特に制限されず、通常用いられ る一般的な測定方法が使用される。 [0023] The amount of substance P can be measured more easily with better reproducibility by measuring a force protein that can be expressed by the amount of substance P mRNA or the amount of protein. Hereinafter, when expressed as the amount of substance P, unless otherwise specified, the amount (protein content) of substance P itself is measured. Yes. When measuring the amount of substance P, it is preferable to immediately collect the culture supernatant immediately after the treatment of the cultured cells and the like and to start the measurement immediately. The measurement is performed within 1 hour, preferably within tens of minutes, more preferably within 30 minutes, more preferably within 10 minutes, more preferably within 5 minutes, particularly preferably within a few minutes to a few seconds from the collection of the supernatant. Start. Considering the time required for the operation, the culture is usually performed within 0.5 minutes to 1 hour, preferably within 110 minutes, even more preferably within 110 minutes, and most preferably within 15 minutes. What is necessary is just to start measuring the amount of substance P during the cleaning. The measurement method is not particularly limited, and a commonly used general measurement method is used.
サブスタンス P量は培養液上清中の量を直接測定してもよレ、が、例えば、 ELISA法 またはィムノクロマトグラフィー法などの抗体を用いることにより間接的に測定すること もできる。サブスタンス Pを直接測定する方法としては、高速液体クロマトグラフィー等 が挙げられるが、これに限定するわけではない。間接的に測定する方法としては、抗 サブスタンス P抗体を用いた免疫学的測定方法が好ましぐ通常使用される競合法 やサンドイッチアツセィ法等が使用できる力 これに限定するわけではない。標識抗 体としては、直接標識 (金コロイド、蛍光物質などの標識)や酵素標識した抗体を用い ること力 Sできる。測定に用いる抗体は市販されているものを用いる力、当業者に公知 の方法で作製することができる。抗サブスタンス P抗体としては、モノクローナル抗体 やポリクローナル抗体を用いることができ、市販品として、サンタクルズ社またはザィメ ット社などから入手できる。また、サブスタンス P量測定キットとしては、市販のものを使 用することができ、サブスタンス P ELISA(R&D Systems Inc.), Substance P, EIA Kit(Cayman Chemical Company)や Substance P, EIA High Sensitivity Kit (Peninsula Laboratories, Inc.)等が挙げられる。競合法を使用した ELISA法によるサブスタンス P 量の測定方法を例に挙げると、培養上清とサブスタンス P標準溶液を、適当量の抗ゥ サギポリクローナル抗体(ャギ)をコートした 96 Wellプレートに添加後、アルカリフォス ファターゼ標識したサブスタンス P溶液を添カ卩し、さらに抗サブスタンス Pポリクローナ ル抗体 (ゥサギ)を添加して室温で反応させる。 2時間反応後、界面活性剤入りの洗 浄液でプレートを十分に洗浄し、基質(pNPP:p-nitrophenyl phosphate)溶液を加え、 室温で 1時間反応後、 TSP (trisodium phosphate)を加え反応を停止させた後、吸光 度 (405nm)を測定し、サブスタンス P標準溶液より得られた結果から作製した検量線 を用いてサブスタンス P量を算出する。 The amount of substance P may be measured directly by measuring the amount in the supernatant of the culture solution, but can also be measured indirectly by using an antibody such as ELISA or immunochromatography. Examples of a method for directly measuring substance P include, but are not limited to, high performance liquid chromatography. The method of indirect measurement is not limited to the ability to use a commonly used competitive method or sandwich attestation method, which is preferably an immunological measurement method using an anti-substance P antibody. As a labeled antibody, a direct label (a label such as colloidal gold or a fluorescent substance) or an enzyme-labeled antibody can be used. Antibodies used for the measurement can be prepared by using commercially available antibodies or by methods known to those skilled in the art. As the anti-substance P antibody, a monoclonal antibody or a polyclonal antibody can be used, and a commercially available product can be obtained from Santa Cruz or Zymmet. A commercially available substance P amount measurement kit can be used.Substance P ELISA (R & D Systems Inc.), Substance P, EIA Kit (Cayman Chemical Company), Substance P, EIA High Sensitivity Kit ( Peninsula Laboratories, Inc.). As an example of the method of measuring the amount of substance P by ELISA using the competitive method, add the culture supernatant and the substance P standard solution to a 96-well plate coated with an appropriate amount of anti-magpie polyclonal antibody (goat). Thereafter, a substance P solution labeled with alkaline phosphatase is added, and an anti-substance P polyclonal antibody (Egret) is added, followed by reaction at room temperature. After reacting for 2 hours, wash the plate thoroughly with a detergent solution containing a surfactant, add a substrate (pNPP: p-nitrophenyl phosphate) solution, react for 1 hour at room temperature, and add TSP (trisodium phosphate). After stopping, absorbance Measure (405 nm) and calculate the amount of substance P using the calibration curve prepared from the results obtained from the substance P standard solution.
[0025] 本発明の評価方法の具体的な態様の一例として、スティンギングを引き起こすこと が知られている化合物を陽性対照として用いた試験系と、被検体を用いた試験系と で培地中のサブスタンス P量を比較する方法が挙げられる。この場合、被検体を用い た試験系の培地中のサブスタンス P量力 陽性対照を用いた試験系の培地中のサブ スタンス P量と同等またはそれ以上であれば、被検体は皮膚に対するスティンギング 刺激性を有すると判断される。しかし、場合によっては、被検体を用いた試験系の培 地中のサブスタンス P量が、陽性対照を用レ、た試験系の培地中のサブスタンス P量の 90%以上、 80%以上、 70%以上、 60%以上、または 50%以上で、被検体が皮膚に 対してスティンギング刺激を有すると判断することもできる。この判断基準は試験目的 、用いる陽性対照等に応じて、適宜、選択される。また、陽性対照としては、フエノキ シエタノール、メチルパラベン、乳酸等を用いることができる力 試験目的、用いる培 養細胞等に応じて、適宜、選択することができる。 [0025] As an example of a specific embodiment of the evaluation method of the present invention, a test system using a compound known to cause stinging as a positive control and a test system using a test subject are used in a medium. A method of comparing the amount of substance P may be mentioned. In this case, if the amount of substance P in the medium of the test system using the subject is equal to or greater than the amount of substance P in the medium of the test system using the positive control, the subject is stinging to the skin. Is determined. However, in some cases, the amount of substance P in the culture medium of the test system using the subject may be 90% or more, 80% or more, and 70% or more of the amount of substance P in the culture medium of the test system using the positive control. Above, 60% or more, or 50% or more, it can be determined that the subject has a stinging stimulus to the skin. This criterion is appropriately selected according to the purpose of the test, the positive control to be used, and the like. In addition, a positive control can be appropriately selected depending on the purpose of a force test in which phenoxyethanol, methylparaben, lactic acid, and the like can be used, the cultured cells to be used, and the like.
[0026] また、本発明の他の態様として、上記のような陽性対照を用いることなぐ被検体を 評価することができる。例えば、被検体を皮膚構成培養細胞等と接触させ、培地中に 検出される細胞由来のサブスタンス P量を指標として、被験体のスティンギング刺激を 評価することが可能である。この方法では、上記と同様にして皮膚構成培養細胞等を 処理し、培養上清を採取し、上清中のサブスタンス P量を測定する。この態様に使用 しうる細胞や皮膚モデル、培養条件、サブスタンス Pの測定および評価法等は実質 上、前記と同様である。具体例として、正常ヒト表皮ケラチノサイトを用いる評価方法 の場合、好ましくは、培養上清採取力 5分後に該上清中に検出されたサブスタンス P量が約 2.5pg/l X 105細胞以上である場合にスティンギング刺激偽陽性、約 lOpg/1 X 105細胞以上である場合にスティンギング刺激陽性と判断できる。この態様の評価 法は、ヒトでのスティンギング試験の前の一次スクリーニングとして特に有用である。力 ットオフ値は希望に応じて適宜設定できる。 [0026] In another embodiment of the present invention, a subject can be evaluated without using a positive control as described above. For example, it is possible to evaluate the stinging stimulus of a subject by bringing the subject into contact with cultured skin cells or the like, and using the amount of the substance P derived from the cells detected in the medium as an index. In this method, cultured skin constituent cells and the like are treated in the same manner as described above, the culture supernatant is collected, and the amount of substance P in the supernatant is measured. The cells and skin model, culture conditions, and the method for measuring and evaluating substance P that can be used in this embodiment are substantially the same as described above. As a specific example, the case of the evaluation methods using normal human epidermal keratinocytes, are preferably, substance P amount detected on the upper brass five minutes after the culture supernatant harvested force of about 2.5 pg / l X 10 5 cells or more In this case, the stinging stimulus is false positive, and when it is about lOpg / 1 × 10 5 cells or more, it can be determined that the stinging stimulus is positive. The evaluation method of this embodiment is particularly useful as a primary screening before a stinging test in humans. The power-off value can be set appropriately as desired.
[0027] このようにして、本評価方法により、被検体による皮膚構成細胞におけるサブスタン ス Pの放出量を指標とするスティンギング刺激の陽性物質または陽性製剤のスクリー ニング方法が提供される。本発明の評価方法は従来の感覚的な判断手法に依存す るものではなぐ各被検体について客観的かつ定量的な評価を与えることができ、簡 便なスクリーニング方法として有用である。 [0027] In this manner, according to the present evaluation method, the screen of the positive substance or the positive preparation of the stinging stimulus using the release amount of substance P in the skin constituent cells by the subject as an index is obtained. A method is provided. The evaluation method of the present invention does not rely on a conventional sensory judgment method, can provide an objective and quantitative evaluation for each subject, and is useful as a simple screening method.
[0028] また、本発明は、被検体の皮膚刺激性を予測するための測定キットを提供する。こ のキットは、スティンギング刺激陽性物質と接触するとサブスタンス Pを放出する皮膚 構成培養細胞等、およびサブスタンス Pの量を測定するための試薬を含む。サブスタ ンス Pの量を測定するための試薬としては、抗サブスタンス P抗体、標識化抗サブスタ ンス P抗体、標識化サブスタンス P (溶液)、対照標準として用いるための既知量のサ ブスタンス P等が挙げられる力 これらに限定されしなレ、。さらに、陽性対照品として、 フエノキシエタノール、メチルパラベン、乳酸等のスティンギング刺激陽性物質、好ま しくはメチルパラベンを含むこともできる。具体的には、キット構成物として、表皮ケラ チノサイトを播種した培養器、表皮ケラチノサイト用培養液、サブスタンス P量測定用 試薬を含む。このサブスタンス P量測定用試薬は、例えば、サブスタンス P量測定用 ELISA試薬である。さらに、このキットは陽性対照としてメチルパラベンを含んでも良 レ、。本キットは、例えば、表皮ケラチノサイトを 96Wellプレートに適当量播種して調製 したプレートに、被検体を分散あるいは溶解させた培養液を添加して細胞を刺激し、 一定時間後に培地上清中のサブスタンス P量をサブスタンス P量測定用 ELISA試薬 を用いて測定することで使用できる。 [0028] The present invention also provides a measurement kit for predicting skin irritation of a subject. This kit contains, for example, cultured skin constituent cells that release substance P upon contact with a stinging stimulus-positive substance, and reagents for measuring the amount of substance P. Examples of reagents for measuring the amount of substance P include anti-substance P antibody, labeled anti-substance P antibody, labeled substance P (solution), and a known amount of substance P to be used as a control standard. Power that is not limited to these. Further, as a positive control, a stinging stimulus-positive substance such as phenoxyethanol, methylparaben, or lactic acid, preferably methylparaben may be contained. Specifically, the kit composition includes an incubator inoculated with epidermal keratinocytes, a culture solution for epidermal keratinocytes, and a reagent for measuring the amount of substance P. The substance P amount measurement reagent is, for example, a substance P amount measurement ELISA reagent. In addition, this kit may contain methyl paraben as a positive control. This kit, for example, stimulates cells by adding a culture solution in which a test sample is dispersed or dissolved to a plate prepared by seeding an appropriate amount of epidermal keratinocytes on a 96-well plate, and stimulating cells after a certain period of time. It can be used by measuring the amount of P using an ELISA reagent for measuring the amount of substance P.
本発明の他の態様 (比較対照を使用しない評価方法)に関する測定キットも上記に 準じて構成することができるが、そのようなキットの構築方法は当業者に既知である。 実施例 A measurement kit for another embodiment of the present invention (evaluation method without using a comparison control) can also be constituted according to the above, and a method for constructing such a kit is known to those skilled in the art. Example
[0029] 以下に実施例を挙げて本発明を説明するが、本発明はこれらの実施例に限定され るものではない。 [0029] Hereinafter, the present invention will be described with reference to examples, but the present invention is not limited to these examples.
[0030] 実施例 1 サブスタンス P量の測定およびその量とスティンギング刺激との相関 Example 1 Measurement of Substance P Level and Correlation between the Level and Stinging Stimulation
サブスタンス P量は ELISA法により測定した。 2 X 105cells/wellとなるよう、正常ヒト表 皮ケラチノサイト(Epidercell NHEK(B))を 24Wellプレートに播種し、表皮ケラチノサイ ト用培地 KG-2 (クラボウ社製) lmlを用いて 37°C、 5% CO下で培養した。サブコンフ ルェントとなった時点で培地交換し、ゥエル内で所定の最終濃度になるように調製し た各被検体試料を 10 / 1ずつ添加した。その 5分後および 10分後に培養上清を回収 した。回収した培養上清中のサブスタンス Pをサブスタンス P ELISA (R&D Systems Inc.製)により定量した。その後、通常の方法により各ゥエルの細胞数を測定した。そ の結果を表 1に示す。被検体として、フエノキシエタノールおよびメチルパラベンを用 レ、た。フエノキシエタノールおよびメチルパラベンの刺激はスティンギング刺激である ことが知られている。 The substance P amount was measured by the ELISA method. Normal human epidermal keratinocytes (Epidercell NHEK (B)) were seeded on a 24-well plate at 2 x 10 5 cells / well, and 37 ° C using 1 ml of epidermal keratinocyte culture medium KG-2 (Kurabo). And cultured under 5% CO. When the medium becomes subconfluent, replace the medium and adjust to the specified final concentration in the well. Each of the test samples was added in an amount of 10/1. The culture supernatant was collected 5 minutes and 10 minutes thereafter. Substance P in the collected culture supernatant was quantified by substance P ELISA (manufactured by R & D Systems Inc.). Thereafter, the number of cells in each well was measured by an ordinary method. The results are shown in Table 1. Phenoxyethanol and methylparaben were used as test subjects. The stimuli of phenoxyethanol and methylparaben are known to be stinging stimuli.
[0031] スティンギング刺激の言平価 [0031] Stinging Stimulus Word Parity
敏感肌の専用パネラー 10人に対して、 目尻から小鼻にかけての頰部に水を加えて 所定の最終濃度に調整した各被検体試料を O. lmr塗布し、塗布直後、 2.5分後、 5分 後に以下の評価基準に従って評点を求め、その 3回の平均評点で評価を行った。評 価基準は次の通りである。 For 10 panelists with sensitive skin, apply O.lmr to each subject sample adjusted to a predetermined final concentration by adding water to the area from the outer corner of the eyes to the nostrils, immediately after application, 2.5 minutes, and 5 minutes. Later, a score was obtained according to the following evaluation criteria, and the evaluation was performed using the average of the three times. The evaluation criteria are as follows.
評点 0 · · ·全く刺激を感じない Rating 0 · · · No stimulation at all
評点 1 · · ·少し感じる Rating 1 · · · A little
評点 2 · "感じる Rating 2 · "Feel
評点 3 · · ·非常に感じる Rating 3 · · · Very Feeling
[0032] [表 1] [Table 1]
[0033] この結果から、サブスタンス Ρ量とスティンギング刺激に相関が認められ、表皮ケラ チノサイトを培養細胞とし、サブスタンス Ρ量を指標とする本評価方法は、スティンギン グ試験の代替方法として有用であることがわかった。 [0033] From these results, a correlation was observed between the substance amount and the stinging stimulation, and this evaluation method using epidermal keratinocytes as cultured cells and using the substance amount as an index is useful as an alternative method to the stinging test. I understand.
産業上の利用可能性 Industrial applicability
[0034] 本評価法は、培養液中の皮膚構成細胞から放出されるサブスタンス Ρ量を指標とし て、被検体の有する皮膚刺激感を予測する方法であり、皮膚トラブルを引き起こす可 能性がある成分や組成物を in vitroで簡便に選別できるため、特に外用剤の開発に 有用である。さらに、本発明によれば、防腐剤、界面活性剤または有機酸およびこれ らを含有する化粧料等の外用剤の皮膚刺激性を in vitroで高感度に評価することが できる。 [0034] This evaluation method uses the amount of substance released from the skin constituent cells in the culture solution as an index. It is a method for predicting the skin irritation of a subject, and it is particularly useful for the development of external preparations because components and compositions that may cause skin troubles can be easily selected in vitro. Furthermore, according to the present invention, skin irritation of an external preparation such as a preservative, a surfactant or an organic acid and a cosmetic containing them can be evaluated in vitro with high sensitivity.
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006510292A JPWO2005080977A1 (en) | 2004-02-24 | 2005-02-23 | Skin irritation evaluation method |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004048501 | 2004-02-24 | ||
| JP2004-048501 | 2004-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2005080977A1 true WO2005080977A1 (en) | 2005-09-01 |
Family
ID=34879517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2005/002902 Ceased WO2005080977A1 (en) | 2004-02-24 | 2005-02-23 | Method of estimating skin irritation |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPWO2005080977A1 (en) |
| WO (1) | WO2005080977A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05336996A (en) * | 1992-06-12 | 1993-12-21 | Koken Co Ltd | Method for testing cytotoxicity with cultured cell |
| JPH06180311A (en) * | 1991-01-28 | 1994-06-28 | Procter & Gamble Co:The | Method of evaluating skin irritability |
| JP2002062294A (en) * | 2000-08-23 | 2002-02-28 | Shiseido Co Ltd | Method and device for measuring skin surface condition |
| JP2003240779A (en) * | 2002-02-15 | 2003-08-27 | Toyobo Co Ltd | Test method for irritation |
| JP2003238986A (en) * | 2002-02-22 | 2003-08-27 | Shiseido Co Ltd | Inhibitor for increase of substance p |
-
2005
- 2005-02-23 JP JP2006510292A patent/JPWO2005080977A1/en active Pending
- 2005-02-23 WO PCT/JP2005/002902 patent/WO2005080977A1/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06180311A (en) * | 1991-01-28 | 1994-06-28 | Procter & Gamble Co:The | Method of evaluating skin irritability |
| JPH05336996A (en) * | 1992-06-12 | 1993-12-21 | Koken Co Ltd | Method for testing cytotoxicity with cultured cell |
| JP2002062294A (en) * | 2000-08-23 | 2002-02-28 | Shiseido Co Ltd | Method and device for measuring skin surface condition |
| JP2003240779A (en) * | 2002-02-15 | 2003-08-27 | Toyobo Co Ltd | Test method for irritation |
| JP2003238986A (en) * | 2002-02-22 | 2003-08-27 | Shiseido Co Ltd | Inhibitor for increase of substance p |
Non-Patent Citations (3)
| Title |
|---|
| BAE S.J. ET AL: "Autocrine induction of substanc P mRNA and peptide in cultured normal human keratinocytes.", BBRC., vol. 263, 1999, pages 327 - 333, XP002992158 * |
| KATAYAMA I. ET AL: "Stress response, tachykinin, and cutaneous inflammation.", JID SYMPOSIUM PROCEEDINGS., vol. 6, no. 1, November 2001 (2001-11-01), pages 81 - 86, XP002992157 * |
| TOYODA M. ET AL: "Skin and the Nervous System", JPN. J. DERMATOL, vol. 109, no. 5, 1999, pages 725 - 737, XP002992156 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2005080977A1 (en) | 2007-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Baswan et al. | Understanding the formidable nail barrier: A review of the nail microstructure, composition and diseases | |
| Ishikawa et al. | Variations in the ceramide profile in different seasons and regions of the body contribute to stratum corneum functions | |
| US9168215B2 (en) | Cosmetic use of lacritin-type polypeptides | |
| US20080131902A1 (en) | Personalized skin care composition and method for production thereof | |
| US11892447B2 (en) | Method for evaluating the effects of dehydration on children's skin | |
| EP2618808B1 (en) | Cosmetic use of dermicidin and fragments thereof | |
| KR20220009424A (en) | How to choose a skin treatment regimen, ingredients and compositions | |
| Dickel et al. | The “strip” patch test: results of a multicentre study towards a standardization | |
| TWI580964B (en) | Method for evaluating stress accumulation degree of skin | |
| CN116209397A (en) | Minimally invasive skin condition diagnostic kit including microneedle patch | |
| US10837958B2 (en) | Method for evaluating the harmful effects of urine on children's skin | |
| EP2880439B1 (en) | Surface isotropy as a marker for epidermal maturation | |
| KR20150072567A (en) | Method for estimating skin whitening effect of cosmetic composition | |
| TWI595235B (en) | Method for evaluating rough skin | |
| US10060931B2 (en) | Use of complex forms of calmodulin-like skin protein CLSP | |
| TWI600904B (en) | Method of evaluating degree of skin stress accumulation | |
| WO2005080977A1 (en) | Method of estimating skin irritation | |
| JP2011083207A (en) | Method for evaluating epidermal turnover and application thereof | |
| Caucanas et al. | Dynamics of skin barrier repair following preconditioning by a biotechnology‐driven extract from samphire (Crithmum maritimum) stem cells | |
| JP2021117164A (en) | Method of evaluating skin inflammatory conditions | |
| KR101766393B1 (en) | Screening method for materials improving dry skin using bleomycin hydrolase | |
| JP2016216436A (en) | Skin viscoelasticity improver | |
| Said | Effect of Hand Hygiene Procedures on Skin Biomarkers | |
| Robinson et al. | 34 Noninvasive Clinical Assessment | |
| Dauskardt | Keynote Lectures |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2006510292 Country of ref document: JP |
|
| 122 | Ep: pct application non-entry in european phase |